1257 Risk of developing brain metastasis with BRCA mutation from ovarian cancer: retrospective monocentric study

Introduction/Background Brain metastases (BMs) from ovarian cancer (OC) are extremely rare and have a very poor prognosis. With presense BRCA mutation the risk of developing brain metastasis becomes higher. Objective We aimed to analyze the risk of developing brain metastasis from ovarian cancer (OC), fallopian tube carcinoma (FTC) and primary peritoneal carcinoma (PPC) in a single center experience. Methodology All women with OC, FTC and PPC with BMs, who were treated in Oncogynecological Department of N.N. Alexandrov National Cancer Centre of Belarus between January 1980 and December 2022 were retrospectively identified. The main criteria were serous carcinoma, endometrioid carcinoma and clear cell carcinoma and brain metastases. Results A total of 106 patients were analyzed: all patients with OC. The mean was 61.42 ± 9.94 (95% CI [59.52; 63.32]) years. We could only use blocks suitable for PCR studies in 25 patients, A total of 9 mutations were identified. Analysis of the spectrum of gene disorders showed the predominance of the pathogenic variant c.5266dupC (in 44.4% of cases), pathogenic variants 181T>G and c.4035delA were found in 33.3% and 22.3% of cases, respectively. The risk of developing brain metastases in patients with ovarian cancer and a BRCA mutation were calculated using contingency tables. To elucidate the indicators, the presence of a BRCA mutation was used as a risk factor; the outcome was the development of brain metastasis. Thus, the relative risk of developing brain metastases in the presence of a BRCA mutation in patients with ovarian cancer is 1.07 (95% CI [0.51, 2.45]. Conclusion The relative risk of developing brain metastases with BRCA mutation in patients with ovarian cancer is not higer (1.07). For a more accurate conclusion it`s required a larger sample collection and prospective date. Disclosures No disclosures.